Home » Business » Manufacturing
Qiagen optimistic
By Cathy Ding |
July 30, 2010, Friday
|
Print Edition
Print Edition
GERMAN biotechnology firm Qiagen hopes its revenue in China will nearly double this year with increasing demand for molecular testing.
The company, which provides sample and assay technologies for research institutions and pharmaceutical firms, has seen revenue increase more than 90 percent in China in the past year while that of the Asian Pacific region jumped about 40 percent.
Asia Pacific now contributes 15 percent of its global revenue, according to Victor Shi, president of Qiagen Asia Pacific.
The company has production bases in Shenzhen and Beijing.
The company, which provides sample and assay technologies for research institutions and pharmaceutical firms, has seen revenue increase more than 90 percent in China in the past year while that of the Asian Pacific region jumped about 40 percent.
Asia Pacific now contributes 15 percent of its global revenue, according to Victor Shi, president of Qiagen Asia Pacific.
The company has production bases in Shenzhen and Beijing.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
